董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jerzy Gumulka | 男 | Director | 76 | 5.09万美元 | 未持股 | 2026-01-01 |
| Faith L. Charles | 女 | Chair of the Board and Director | 65 | 7.89万美元 | 未持股 | 2026-01-01 |
| Bettina M. Cockroft | 女 | Director | 59 | 5.29万美元 | 未持股 | 2026-01-01 |
| Amy Mahery | 女 | Director | 49 | 4.68万美元 | 未持股 | 2026-01-01 |
| Rami Levin | 男 | Director,Chief Executive Officer and President | 56 | 未披露 | 未持股 | 2026-01-01 |
| Jeffry R. Keyes | 男 | Director | 53 | 5.98万美元 | 未持股 | 2026-01-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Donald Picker | 男 | Chief Science Officer | 80 | 0.41万美元 | 未持股 | 2026-01-01 |
| Sandra L. Silberman | 女 | Chief Medical Officer | 71 | 36.16万美元 | 未持股 | 2026-01-01 |
| Christopher S. Downs | 男 | Chief Financial Officer | 48 | 62.11万美元 | 未持股 | 2026-01-01 |
| Rami Levin | 男 | Director,Chief Executive Officer and President | 56 | 未披露 | 未持股 | 2026-01-01 |
董事简历
中英对照 | 中文 | 英文- Jerzy Gumulka
-
Jerzy Gumulka于2017年11月8日加入CNS Pharmaceuticals, Inc.担任董事，他于2016年退休。从2001年到退休，他担任ASC的全球技术经理，Kraton Polymers US LLC的特殊项目/新技术平台的技术经理，Kraton Polymers do Brasil的技术总监。他曾担任Moleculin LLC的董事（2010年至2016年）。他在Warsaw, Poland的Warsaw大学获得博士学位。
Jerzy Gumulka joined board of directors on November 8, 2017. Dr. Gumulka has been retired since 2016. From 2001 until his retirement, he served as a Global Technology Manager ASC, a Technology Manager, Special Projects/New Technology Platforms, Kraton Polymers LLC, and a Technical Director of Kraton Polymers do Brasil. Prior to his employment at Shell Chemical Company and Kraton Polymers LLC, Dr. Gumulka worked at BioSpectrum, Inc. (aka IML) and was involved in the development and application of Human Immune Interferon (INF γ) and Interleukin 2 in the HIV foced clinical studies and animal models. Dr. Gumulka co authored patents on the production and purification of INF γ and Interleukin 2, and in the field of analytical chemistry, environmental and polymer science. Dr. Gumulka is the recipient of the 2011 Presidential Green Chemistry Challenge Award. Dr. Gumulka served on the Board of Directors of Moleculin LLC from 2010 through 2016. Dr. Gumulka received a Ph.D. from the University of Warsaw, Warsaw, Poland. - Jerzy Gumulka于2017年11月8日加入CNS Pharmaceuticals, Inc.担任董事，他于2016年退休。从2001年到退休，他担任ASC的全球技术经理，Kraton Polymers US LLC的特殊项目/新技术平台的技术经理，Kraton Polymers do Brasil的技术总监。他曾担任Moleculin LLC的董事（2010年至2016年）。他在Warsaw, Poland的Warsaw大学获得博士学位。
- Jerzy Gumulka joined board of directors on November 8, 2017. Dr. Gumulka has been retired since 2016. From 2001 until his retirement, he served as a Global Technology Manager ASC, a Technology Manager, Special Projects/New Technology Platforms, Kraton Polymers LLC, and a Technical Director of Kraton Polymers do Brasil. Prior to his employment at Shell Chemical Company and Kraton Polymers LLC, Dr. Gumulka worked at BioSpectrum, Inc. (aka IML) and was involved in the development and application of Human Immune Interferon (INF γ) and Interleukin 2 in the HIV foced clinical studies and animal models. Dr. Gumulka co authored patents on the production and purification of INF γ and Interleukin 2, and in the field of analytical chemistry, environmental and polymer science. Dr. Gumulka is the recipient of the 2011 Presidential Green Chemistry Challenge Award. Dr. Gumulka served on the Board of Directors of Moleculin LLC from 2010 through 2016. Dr. Gumulka received a Ph.D. from the University of Warsaw, Warsaw, Poland.
- Faith L. Charles
-
Faith L. Charles于2022年12月30日加入Cns Pharmaceuticals，Inc.董事会，目前担任董事会主席。自2010年以来，查尔斯一直是Thompson Hine，LLP律师事务所的公司交易和证券合伙人。她领导Thompson Hine的生命科学业务，并担任证券业务联席主管，为美国和国际上的上市和新兴生物技术及制药公司提供咨询。查尔斯女士负责谈判复杂的私人和公共融资交易、兼并和收购、许可交易和战略合作。她是众多生命科学公司的外部顾问，在业内被称为精明的商业顾问，为资本市场、公司治理和战略发展提供宝贵的见解。从2018年到2021年10月，查尔斯女士担任上市生物技术公司Entera Bio的董事会成员、审计委员会成员和薪酬委员会主席。她还担任多家私营生命科学公司的董事会成员。查尔斯女士创立了纽约都市生物区妇女分会，并担任该分会主席长达五年。她目前在国家生物妇女委员会任职。查尔斯女士还是Red Door Community（前身为Gilda's Club New York City）的董事会成员。她被Euromoney的LMG Life Sciences评为生命科学明星，被评为BTI客户服务全明星，并被Crain的《纽约商业》评选为2020年度法律领域的杰出女性。Charles女士拥有乔治华盛顿大学法学院的京东学位和哥伦比亚大学巴纳德学院的心理学学士学位。查尔斯毕业于乔治华盛顿大学商学院教授的“女性进入生物公司”的“董事会会议室就绪计划”。
Faith L. Charles joined board of directors on December 30, 2022 and currently serves as chair of the board of directors. Ms. Charles has been a corporate transactions and securities partner at the law firm of Thompson Hine, LLP, since 2010. She leads Thompson Hine's Life Sciences practice and co heads the securities practice, advising public and emerging biotech and pharmaceutical companies in the U.S. and internationally. Ms. Charles negotiates complex private and public financing transactions, mergers and acquisitions, licensing transactions and strategic collaborations. She serves as outside counsel to a myriad of life sciences companies and is known in the indtry as an astute biness advisor, providing valuable insights into capital markets, corporate governance and strategic development. From 2025 to present, Ms. Charles has served on the board of directors and as a member of the compensation committee and chair of the nominating and governance committee of Abeona Therapeutics, Inc., a publicly traded biotechnology company. From 2021 to present, Ms. Charles has served on the board of directors and as a member of the audit committee and as a member of the compensation committee of Avenue Therapeutics, Inc., a publicly traded biotechnology company. From 2018 until October 2021, Ms. Charles served on the board of directors and as a member of the audit committee and chair of the compensation committee of Entera Bio, a publicly traded biotechnology company. She also serves on the Board of Directors of several private life science companies. Ms. Charles founded the Women in Bio Metro New York chapter and chaired the chapter for five years. She currently serves on the national board of Women in Bio. Ms. Charles is also a member of the board of Red Door Community (formerly Gilda's Club New York City). She has been recognized as a Life Sciences Star by Euromoney's LMG Life Sciences, has been named a BTI Client Service All Star, and was named by Crain's New York Biness to the list of 2020 Notable Women in the Law. Ms. Charles holds a J.D. degree from The George Washington University Law School and a B.A. in Psychology from Barnard College, Columbia University. Ms. Charles is a graduate of Women in Bio's Boardroom Ready Program, an Executive Education Program taught by The George Washington University School of Biness. - Faith L. Charles于2022年12月30日加入Cns Pharmaceuticals，Inc.董事会，目前担任董事会主席。自2010年以来，查尔斯一直是Thompson Hine，LLP律师事务所的公司交易和证券合伙人。她领导Thompson Hine的生命科学业务，并担任证券业务联席主管，为美国和国际上的上市和新兴生物技术及制药公司提供咨询。查尔斯女士负责谈判复杂的私人和公共融资交易、兼并和收购、许可交易和战略合作。她是众多生命科学公司的外部顾问，在业内被称为精明的商业顾问，为资本市场、公司治理和战略发展提供宝贵的见解。从2018年到2021年10月，查尔斯女士担任上市生物技术公司Entera Bio的董事会成员、审计委员会成员和薪酬委员会主席。她还担任多家私营生命科学公司的董事会成员。查尔斯女士创立了纽约都市生物区妇女分会，并担任该分会主席长达五年。她目前在国家生物妇女委员会任职。查尔斯女士还是Red Door Community（前身为Gilda's Club New York City）的董事会成员。她被Euromoney的LMG Life Sciences评为生命科学明星，被评为BTI客户服务全明星，并被Crain的《纽约商业》评选为2020年度法律领域的杰出女性。Charles女士拥有乔治华盛顿大学法学院的京东学位和哥伦比亚大学巴纳德学院的心理学学士学位。查尔斯毕业于乔治华盛顿大学商学院教授的“女性进入生物公司”的“董事会会议室就绪计划”。
- Faith L. Charles joined board of directors on December 30, 2022 and currently serves as chair of the board of directors. Ms. Charles has been a corporate transactions and securities partner at the law firm of Thompson Hine, LLP, since 2010. She leads Thompson Hine's Life Sciences practice and co heads the securities practice, advising public and emerging biotech and pharmaceutical companies in the U.S. and internationally. Ms. Charles negotiates complex private and public financing transactions, mergers and acquisitions, licensing transactions and strategic collaborations. She serves as outside counsel to a myriad of life sciences companies and is known in the indtry as an astute biness advisor, providing valuable insights into capital markets, corporate governance and strategic development. From 2025 to present, Ms. Charles has served on the board of directors and as a member of the compensation committee and chair of the nominating and governance committee of Abeona Therapeutics, Inc., a publicly traded biotechnology company. From 2021 to present, Ms. Charles has served on the board of directors and as a member of the audit committee and as a member of the compensation committee of Avenue Therapeutics, Inc., a publicly traded biotechnology company. From 2018 until October 2021, Ms. Charles served on the board of directors and as a member of the audit committee and chair of the compensation committee of Entera Bio, a publicly traded biotechnology company. She also serves on the Board of Directors of several private life science companies. Ms. Charles founded the Women in Bio Metro New York chapter and chaired the chapter for five years. She currently serves on the national board of Women in Bio. Ms. Charles is also a member of the board of Red Door Community (formerly Gilda's Club New York City). She has been recognized as a Life Sciences Star by Euromoney's LMG Life Sciences, has been named a BTI Client Service All Star, and was named by Crain's New York Biness to the list of 2020 Notable Women in the Law. Ms. Charles holds a J.D. degree from The George Washington University Law School and a B.A. in Psychology from Barnard College, Columbia University. Ms. Charles is a graduate of Women in Bio's Boardroom Ready Program, an Executive Education Program taught by The George Washington University School of Biness.
- Bettina M. Cockroft
-
Bettina Cockroft于2023年5月3日加入Cns Pharmaceuticals，Inc.董事会。2019年9月至2023年5月，科克罗夫特博士担任上市生物技术公司Sangamo Therapeutics, Inc.的高级副总裁兼首席医疗官，负责临床开发活动和运营。她在生物制药行业拥有超过20年的经验，曾在多个治疗领域工作，并在多个国家领导项目。在加入Sangamo之前，Cockroft博士是Cytokinetics公司的高级领导团队成员，该公司是一家上市的生物制药公司，在那里她负责开发用于肌萎缩性侧索硬化症和脊髓性肌萎缩症等疾病的快速骨骼肌肌钙蛋白激活剂。2017年8月至2019年9月，她在Cytokinetics担任神经学临床研究副总裁。从2016年10月到2017年7月，科克罗夫特博士担任制药执行顾问，在此之前，从2013年9月到2016年9月，她担任生物制药公司Auris Medical AG的首席医疗官，在那里，她领导并发展了负责两个3期项目的临床开发团队。科克罗夫特博士在职业生涯早期还在默沙东雪兰诺公司、诺华消费者健康公司和美纳里尼公司担任过越来越重要的职务。科克罗夫特博士自2022年1月起担任Annexon公司董事会成员。考克罗夫特博士获得了麻省理工学院斯隆管理学院的工商管理硕士学位和热那亚大学的医学博士学位。
Bettina M. Cockroft joined board on May 3, 2023. Since January 2025, Dr. Cockroft serves as Chief Medical Officer of Cilcare Inc., a biotech company developing therapeutics for hearing disorders. From September 2019 to May 2023, Dr. Cockroft was Senior Vice President and Chief Medical Officer of Sangamo Therapeutics, Inc., a publicly held biotechnology company, where she oversaw clinical development activities and operations. She has over 20 years of experience in the biopharmaceutical indtry and has worked across multiple therapeutic areas and led programs in several countries. Prior to joining Sangamo, Dr. Cockroft served on the senior leadership team at Cytokinetics, Inc., a publicly held biopharmaceutical company, where she was responsible for clinical development of fast skeletal mcle troponin activators in diseases such as Amyotrophic Lateral Sclerosis and Spinal Mcular Atrophy. She served as Vice President, Clinical Research, Neurology, at Cytokinetics from Augt 2017 to September 2019. From October 2016 to July 2017, Dr. Cockroft served as a pharmaceutical executive consultant, and before that, from September 2013 to September 2016, she served as Chief Medical Officer of Auris Medical AG, a biopharmaceutical company, where she led and grew the clinical development team responsible for two Phase 3 programs. Dr. Cockroft also held roles of increasing responsibility at Merck Serono S.A., Novartis Consumer Health and Menarini Ricerche earlier in her career. Dr. Cockroft has served as a member of the board of directors of Annexon, Inc. since January 2022 including serving as a member of the audit committee and the science and technology committee. Dr. Cockroft received a M.B.A. from MIT Sloan School of Management and a M.D. from the University of Genova. - Bettina Cockroft于2023年5月3日加入Cns Pharmaceuticals，Inc.董事会。2019年9月至2023年5月，科克罗夫特博士担任上市生物技术公司Sangamo Therapeutics, Inc.的高级副总裁兼首席医疗官，负责临床开发活动和运营。她在生物制药行业拥有超过20年的经验，曾在多个治疗领域工作，并在多个国家领导项目。在加入Sangamo之前，Cockroft博士是Cytokinetics公司的高级领导团队成员，该公司是一家上市的生物制药公司，在那里她负责开发用于肌萎缩性侧索硬化症和脊髓性肌萎缩症等疾病的快速骨骼肌肌钙蛋白激活剂。2017年8月至2019年9月，她在Cytokinetics担任神经学临床研究副总裁。从2016年10月到2017年7月，科克罗夫特博士担任制药执行顾问，在此之前，从2013年9月到2016年9月，她担任生物制药公司Auris Medical AG的首席医疗官，在那里，她领导并发展了负责两个3期项目的临床开发团队。科克罗夫特博士在职业生涯早期还在默沙东雪兰诺公司、诺华消费者健康公司和美纳里尼公司担任过越来越重要的职务。科克罗夫特博士自2022年1月起担任Annexon公司董事会成员。考克罗夫特博士获得了麻省理工学院斯隆管理学院的工商管理硕士学位和热那亚大学的医学博士学位。
- Bettina M. Cockroft joined board on May 3, 2023. Since January 2025, Dr. Cockroft serves as Chief Medical Officer of Cilcare Inc., a biotech company developing therapeutics for hearing disorders. From September 2019 to May 2023, Dr. Cockroft was Senior Vice President and Chief Medical Officer of Sangamo Therapeutics, Inc., a publicly held biotechnology company, where she oversaw clinical development activities and operations. She has over 20 years of experience in the biopharmaceutical indtry and has worked across multiple therapeutic areas and led programs in several countries. Prior to joining Sangamo, Dr. Cockroft served on the senior leadership team at Cytokinetics, Inc., a publicly held biopharmaceutical company, where she was responsible for clinical development of fast skeletal mcle troponin activators in diseases such as Amyotrophic Lateral Sclerosis and Spinal Mcular Atrophy. She served as Vice President, Clinical Research, Neurology, at Cytokinetics from Augt 2017 to September 2019. From October 2016 to July 2017, Dr. Cockroft served as a pharmaceutical executive consultant, and before that, from September 2013 to September 2016, she served as Chief Medical Officer of Auris Medical AG, a biopharmaceutical company, where she led and grew the clinical development team responsible for two Phase 3 programs. Dr. Cockroft also held roles of increasing responsibility at Merck Serono S.A., Novartis Consumer Health and Menarini Ricerche earlier in her career. Dr. Cockroft has served as a member of the board of directors of Annexon, Inc. since January 2022 including serving as a member of the audit committee and the science and technology committee. Dr. Cockroft received a M.B.A. from MIT Sloan School of Management and a M.D. from the University of Genova.
- Amy Mahery
-
艾米·马赫里于2024年2月1日加入董事会。自2025年2月起，Mahery女士担任Moderna, Inc.的首席营销官。自2022年8月至2024年12月，Mahery女士担任Roivant Sciences的首席商务官……从2021年4月至2022年7月，Mahery女士担任EMD Serono，Inc.高级副总裁兼全球特许经营主管-神经病学和免疫学，从2019年至2021年，Mahery女士担任EMD Serono，Inc.高级副总裁兼全球市场准入和定价主管。Mahery女士拥有Hartford三一学院神经科学学士学位。相信Mahery女士在生物制药工业方面的丰富经验为她提供了担任董事的资格。
Amy Mahery joined board on February 1, 2024. Since February 2025, Ms. Mahery has served as Chief Marketing Officer of Moderna, Inc. From Augt 2022 to December 2024, Ms. Mahery served as Chief Commercial Officer of Roivant Sciences.. From April 2021 until July 2022, Ms. Mahery served as Senior Vice President, Global Franchise Head – Neurology & Immunology for EMD Serono, Inc. and from 2019 until 2021 Ms. Mahery served as Senior Vice President, Head – Global Market Access and Pricing for EMD Serono, Inc. Ms. Mahery holds a B.S. degree in Neuroscience from Trinity College Hartford. - 艾米·马赫里于2024年2月1日加入董事会。自2025年2月起，Mahery女士担任Moderna, Inc.的首席营销官。自2022年8月至2024年12月，Mahery女士担任Roivant Sciences的首席商务官……从2021年4月至2022年7月，Mahery女士担任EMD Serono，Inc.高级副总裁兼全球特许经营主管-神经病学和免疫学，从2019年至2021年，Mahery女士担任EMD Serono，Inc.高级副总裁兼全球市场准入和定价主管。Mahery女士拥有Hartford三一学院神经科学学士学位。相信Mahery女士在生物制药工业方面的丰富经验为她提供了担任董事的资格。
- Amy Mahery joined board on February 1, 2024. Since February 2025, Ms. Mahery has served as Chief Marketing Officer of Moderna, Inc. From Augt 2022 to December 2024, Ms. Mahery served as Chief Commercial Officer of Roivant Sciences.. From April 2021 until July 2022, Ms. Mahery served as Senior Vice President, Global Franchise Head – Neurology & Immunology for EMD Serono, Inc. and from 2019 until 2021 Ms. Mahery served as Senior Vice President, Head – Global Market Access and Pricing for EMD Serono, Inc. Ms. Mahery holds a B.S. degree in Neuroscience from Trinity College Hartford.
- Rami Levin
-
拉米·莱文自2024年11月起担任生命科学搜索公司GENerX Life的董事会顾问，并自2024年1月起担任私人控股的咨询和领导力发展公司The Outcomes Group的创始人兼首席执行官。此前，Levin先生于2022年5月至2024年1月期间担任临床阶段生物制药公司ImStem Biotechnology的首席执行官。2019年10月至2022年5月，他担任临床阶段生物制药公司Saniona的总裁兼首席执行官。Levin先生还曾于2017年4月至2021年6月在非营利组织Life Science Cares的顾问委员会任职。Levin先生拥有特拉维夫大学生物学学士学位和MBA学位。
Rami Levin,has served as a Board Advisor for GENerX Life, a life sciences search firm, since November 2024, and as Founder and Chief Executive Officer of The Outcomes Group, a privately held advisory and leadership-development firm, since January 2024. Previously, Mr. Levin served as Chief Executive Officer of ImStem Biotechnology, a clinical-stage biopharmaceutical company, from May 2022 to January 2024. From October 2019 to May 2022, he was President and Chief Executive Officer of Saniona, a clinical-stage biopharmaceutical company. Mr. Levin also served on the Board of Advisors for Life Science Cares, a nonprofit organization, from April 2017 to June 2021. Mr. Levin holds a B.Sc. in Biology and an MBA from Tel Aviv University. - 拉米·莱文自2024年11月起担任生命科学搜索公司GENerX Life的董事会顾问，并自2024年1月起担任私人控股的咨询和领导力发展公司The Outcomes Group的创始人兼首席执行官。此前，Levin先生于2022年5月至2024年1月期间担任临床阶段生物制药公司ImStem Biotechnology的首席执行官。2019年10月至2022年5月，他担任临床阶段生物制药公司Saniona的总裁兼首席执行官。Levin先生还曾于2017年4月至2021年6月在非营利组织Life Science Cares的顾问委员会任职。Levin先生拥有特拉维夫大学生物学学士学位和MBA学位。
- Rami Levin,has served as a Board Advisor for GENerX Life, a life sciences search firm, since November 2024, and as Founder and Chief Executive Officer of The Outcomes Group, a privately held advisory and leadership-development firm, since January 2024. Previously, Mr. Levin served as Chief Executive Officer of ImStem Biotechnology, a clinical-stage biopharmaceutical company, from May 2022 to January 2024. From October 2019 to May 2022, he was President and Chief Executive Officer of Saniona, a clinical-stage biopharmaceutical company. Mr. Levin also served on the Board of Advisors for Life Science Cares, a nonprofit organization, from April 2017 to June 2021. Mr. Levin holds a B.Sc. in Biology and an MBA from Tel Aviv University.
- Jeffry R. Keyes
-
Jeffry R. Keyes，自2012年9月进入本公司，并担任财务总监和企业秘书。自2011年8月至2012年9月，他在Sapphire Energy公司担任财务总监。Sapphire Energy公司是一家新兴的可再生能源公司。自2011年4月至2011年8月，他在Advanced BioHealing公司（现称为Shire Regenerative Medicine）担任财务总监。Advanced BioHealing公司是一家主要提供再生医学解决方案的公司。自2009年3月至2011年4月，他在CareFusion这家全球医疗科技公司担任对外报表和技术会计方面的高级董事。自2008年6月至2009年2月，他在Caterpillar公司担任审计项目经理。Caterpillar公司是一家制造建材和采矿设备的公司。在进入该公司前，他于2005年10月在Plum Creek Timber 公司担任财务报表方面的高级经理。他在Western Washington大学获得会计学学士学位。他获得由华盛顿州会计委员会（Washington State Board of Accountancy）颁发的注册会计师证。
Jeffry R. Keyes joined board on June 25, 2018. Mr. Keyes is currently the Chief Financial Officer of Quantum Si Incorporated, a publicly held proteomics company, a role that he has held since May 2023. From Augt 2022 to May 2023, Mr. Keyes was the Chief Financial Officer of Spinal Elements, Inc., a private equity backed medical device company. From April 2018 to Augt 2022, Mr. Keyes was the Chief Financial Officer of Ctopharm, Inc., a private equity backed developer of generic sterile injectable pharmaceuticals. From September 2012 to April 2018, Mr. Keyes was the Chief Financial Officer and Corporate Secretary of Digirad Corporation, a publicly traded healthcare services and medical device company. From Augt 2011 until September 2012, Mr. Keyes was Corporate Controller of Sapphire Energy, Inc., a venture capital backed start up renewable energy company. From April 2011 to Augt 2011, Mr. Keyes was the Corporate Controller of Advanced BioHealing, Inc., a venture backed provider of regenerative medicine solutions, until its sale to Shire, PLC in Augt 2011. Prior to April 2011 Mr. Keyes held a variety of leadership roles in healthcare and medical device companies in finance, accounting, and M&A support, and he started his career in public accounting. Mr. Keyes earned a B.A. degree in accounting from stern Washington University and is a certified public accountant licensed by the Washington State Board of Accountancy. Mr. Keyes is considered a financial expert under relevant rules of the SEC, the NYSE and Nasdaq. - Jeffry R. Keyes，自2012年9月进入本公司，并担任财务总监和企业秘书。自2011年8月至2012年9月，他在Sapphire Energy公司担任财务总监。Sapphire Energy公司是一家新兴的可再生能源公司。自2011年4月至2011年8月，他在Advanced BioHealing公司（现称为Shire Regenerative Medicine）担任财务总监。Advanced BioHealing公司是一家主要提供再生医学解决方案的公司。自2009年3月至2011年4月，他在CareFusion这家全球医疗科技公司担任对外报表和技术会计方面的高级董事。自2008年6月至2009年2月，他在Caterpillar公司担任审计项目经理。Caterpillar公司是一家制造建材和采矿设备的公司。在进入该公司前，他于2005年10月在Plum Creek Timber 公司担任财务报表方面的高级经理。他在Western Washington大学获得会计学学士学位。他获得由华盛顿州会计委员会（Washington State Board of Accountancy）颁发的注册会计师证。
- Jeffry R. Keyes joined board on June 25, 2018. Mr. Keyes is currently the Chief Financial Officer of Quantum Si Incorporated, a publicly held proteomics company, a role that he has held since May 2023. From Augt 2022 to May 2023, Mr. Keyes was the Chief Financial Officer of Spinal Elements, Inc., a private equity backed medical device company. From April 2018 to Augt 2022, Mr. Keyes was the Chief Financial Officer of Ctopharm, Inc., a private equity backed developer of generic sterile injectable pharmaceuticals. From September 2012 to April 2018, Mr. Keyes was the Chief Financial Officer and Corporate Secretary of Digirad Corporation, a publicly traded healthcare services and medical device company. From Augt 2011 until September 2012, Mr. Keyes was Corporate Controller of Sapphire Energy, Inc., a venture capital backed start up renewable energy company. From April 2011 to Augt 2011, Mr. Keyes was the Corporate Controller of Advanced BioHealing, Inc., a venture backed provider of regenerative medicine solutions, until its sale to Shire, PLC in Augt 2011. Prior to April 2011 Mr. Keyes held a variety of leadership roles in healthcare and medical device companies in finance, accounting, and M&A support, and he started his career in public accounting. Mr. Keyes earned a B.A. degree in accounting from stern Washington University and is a certified public accountant licensed by the Washington State Board of Accountancy. Mr. Keyes is considered a financial expert under relevant rules of the SEC, the NYSE and Nasdaq.
高管简历
中英对照 | 中文 | 英文- Donald Picker
Donald Picker，2007年加入Moleculin，担任首席执行官，自2015年7月起担任首席运营官，2016年1月起担任总裁；2007年成为IntertechBio的首席执行官；2006年至2007年间担任Tapestry Pharmaceuticals的总裁；1998年至2003年间担任Synergy Pharmaceuticals的首席执行官，该公司已与Callisto Pharmaceuticals合并，而他在后者担任研发副总裁直至2006年。他领导研发卡铂（carboplatin）和顺铂（cisplatin）从概念到通过新药审核。这些药物一通过审核便被用于首选化疗药物。他获得了Brooklyn Polytechnic University的学士学位，1975年获得SUNY Albany的博士学位。
Donald Picker has served as part time chief science officer since June 2019. Dr. Picker has served as the chief scientific officer of Moleculin Biotech, Inc. since Augt 2017 after serving as its chief operating officer from July 2015 until Augt 2017 and as its president from January 2016 to Augt 2017. In 2007, Dr. Picker became the chief executive officer of IntertechBio Corp. From 2006 through 2007, Dr. Picker was the President of Tapestry Pharmaceuticals. From 1998 to 2003, Dr. Picker was CEO of Synergy Pharmaceuticals. Synergy was merged into Callisto Pharmaceuticals where he was vice president of research and development until 2006. From 2017 to 2018, Dr. Picker served on board of directors. Dr. Picker received his B.S. degree from Brooklyn Polytechnic University and his PhD from SUNY Albany in 1975. Dr. Picker is currently devoting only 25% of his work time to and provides services as needed to .- Donald Picker，2007年加入Moleculin，担任首席执行官，自2015年7月起担任首席运营官，2016年1月起担任总裁；2007年成为IntertechBio的首席执行官；2006年至2007年间担任Tapestry Pharmaceuticals的总裁；1998年至2003年间担任Synergy Pharmaceuticals的首席执行官，该公司已与Callisto Pharmaceuticals合并，而他在后者担任研发副总裁直至2006年。他领导研发卡铂（carboplatin）和顺铂（cisplatin）从概念到通过新药审核。这些药物一通过审核便被用于首选化疗药物。他获得了Brooklyn Polytechnic University的学士学位，1975年获得SUNY Albany的博士学位。
- Donald Picker has served as part time chief science officer since June 2019. Dr. Picker has served as the chief scientific officer of Moleculin Biotech, Inc. since Augt 2017 after serving as its chief operating officer from July 2015 until Augt 2017 and as its president from January 2016 to Augt 2017. In 2007, Dr. Picker became the chief executive officer of IntertechBio Corp. From 2006 through 2007, Dr. Picker was the President of Tapestry Pharmaceuticals. From 1998 to 2003, Dr. Picker was CEO of Synergy Pharmaceuticals. Synergy was merged into Callisto Pharmaceuticals where he was vice president of research and development until 2006. From 2017 to 2018, Dr. Picker served on board of directors. Dr. Picker received his B.S. degree from Brooklyn Polytechnic University and his PhD from SUNY Albany in 1975. Dr. Picker is currently devoting only 25% of his work time to and provides services as needed to .
- Sandra L. Silberman
Sandra L. Silberman于2017年12月加入CNS，目前兼职服务。她曾担任molecular Biotech, Inc.的新产品首席医疗官（2017年11月以来）。2018年，Silberman博士成为波兰WPD Pharmaceuticals的顾问。在Bristol Myers Squibb、AstraZeneca、Imclone和Roche等领先生物制药公司的工作期间，Silberman博士将几个原创、专有化合物推进到I期至III期。Silberman博士是一名血液学家/肿瘤学家，她获得了学士学位，理学学士学位。以及约翰霍普金斯大学文理学院、公共卫生学院和医学院的博士学位，以及Cornell University医学院的医学博士学位。之后在Brigham & Women医院和Dana Farber癌症研究所完成了血液学/肿瘤学的临床奖学金和肿瘤免疫学的研究奖学金。
Sandra L. Silberman joined CNS in December 2017. Dr. Silberman served as chief medical officer for new products of Moleculin Biotech, Inc. from November 2017 to December 2024 on a part time basis. Dr. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including BristolMyers Squibb, AstraZeneca, Imclone and Roche. Dr. Silberman is a Hematologist/Oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College, and then completed both a clinical fellowship in Hematology/Oncology as ll as a research fellowship in tumor immunology at the Brigham & Women's Hospital and the Dana Farber Cancer Institute in Boston, MA.- Sandra L. Silberman于2017年12月加入CNS，目前兼职服务。她曾担任molecular Biotech, Inc.的新产品首席医疗官（2017年11月以来）。2018年，Silberman博士成为波兰WPD Pharmaceuticals的顾问。在Bristol Myers Squibb、AstraZeneca、Imclone和Roche等领先生物制药公司的工作期间，Silberman博士将几个原创、专有化合物推进到I期至III期。Silberman博士是一名血液学家/肿瘤学家，她获得了学士学位，理学学士学位。以及约翰霍普金斯大学文理学院、公共卫生学院和医学院的博士学位，以及Cornell University医学院的医学博士学位。之后在Brigham & Women医院和Dana Farber癌症研究所完成了血液学/肿瘤学的临床奖学金和肿瘤免疫学的研究奖学金。
- Sandra L. Silberman joined CNS in December 2017. Dr. Silberman served as chief medical officer for new products of Moleculin Biotech, Inc. from November 2017 to December 2024 on a part time basis. Dr. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including BristolMyers Squibb, AstraZeneca, Imclone and Roche. Dr. Silberman is a Hematologist/Oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College, and then completed both a clinical fellowship in Hematology/Oncology as ll as a research fellowship in tumor immunology at the Brigham & Women's Hospital and the Dana Farber Cancer Institute in Boston, MA.
- Christopher S. Downs
Christopher S. Downs，自2019年11月起担任首席财务官。从2018年3月到2019年9月，Downs先生担任Innovative Aftermarket Systems， l.p.的财务副总裁兼财务主管，这是一家私人持有的金融和保险解决方案提供商。Downs先生曾担任财务总监（2011年6月至2013年9月）、副总裁兼财务主管（2013年10月至2016年8月）、执行副总裁兼临时首席财务官（2016年8月至2017年5月）、执行副总裁、临时首席财务官和总裁办公室成员（2017年5月至2018年3月）。Infystem Holdings, Inc.是美国肿瘤学家的信息服务供应商。他在花旗集团（Citigroup）等多家公司的投资银行工作了10年。从2021年3月到2024年7月，Downs先生担任EBET， Inc.（一家技术公司，开发和运营专注于电子竞技和竞技游戏的平台）的董事。他是st Point美国军事学院的毕业生，在那里他获得了理学学士学位。他在哥伦比亚商学院获得工商管理硕士学位，在Hoton Clear Lake大学获得会计硕士学位。他是Utah and Texas的注册会计师。
Christopher S. Downs has served as chief financial officer since November 2019.From March 2018 until September 2019, Mr. Downs served as vice president of finance and treasurer of Innovative Aftermarket Systems, L.P., a privately held provider of finance and insurance solutions. Mr. Downs served as director of finance (from June 2011 to September 2013), vice president and treasurer (October 2013 to Augt 2016), executive vice president and interim chief financial officer (Augt 2016 to May 2017), and executive vice president, interim chief financial officer and member of the office of the president (May 2017 to March 2018) for Infystem Holdings, Inc., a supplier of infion services to oncologists in the United States. Mr. Downs spent 10 years in investment banking with vario firms including Citigroup. Mr. Downs served as a director of EBET, Inc., a technology company developing and operating platforms foced on esports and competitive gaming, from March 2021 to July 2024. Mr. Downs is a graduate of the United States Military Academy at st Point where he earned his Bachelor of Science. Mr. Downs earned his MBA at Columbia Biness School and his Master of Science in Accounting at the University of Hoton Clear Lake. Mr. Downs is a Certified Public Accountant in Utah and Texas.- Christopher S. Downs，自2019年11月起担任首席财务官。从2018年3月到2019年9月，Downs先生担任Innovative Aftermarket Systems， l.p.的财务副总裁兼财务主管，这是一家私人持有的金融和保险解决方案提供商。Downs先生曾担任财务总监（2011年6月至2013年9月）、副总裁兼财务主管（2013年10月至2016年8月）、执行副总裁兼临时首席财务官（2016年8月至2017年5月）、执行副总裁、临时首席财务官和总裁办公室成员（2017年5月至2018年3月）。Infystem Holdings, Inc.是美国肿瘤学家的信息服务供应商。他在花旗集团（Citigroup）等多家公司的投资银行工作了10年。从2021年3月到2024年7月，Downs先生担任EBET， Inc.（一家技术公司，开发和运营专注于电子竞技和竞技游戏的平台）的董事。他是st Point美国军事学院的毕业生，在那里他获得了理学学士学位。他在哥伦比亚商学院获得工商管理硕士学位，在Hoton Clear Lake大学获得会计硕士学位。他是Utah and Texas的注册会计师。
- Christopher S. Downs has served as chief financial officer since November 2019.From March 2018 until September 2019, Mr. Downs served as vice president of finance and treasurer of Innovative Aftermarket Systems, L.P., a privately held provider of finance and insurance solutions. Mr. Downs served as director of finance (from June 2011 to September 2013), vice president and treasurer (October 2013 to Augt 2016), executive vice president and interim chief financial officer (Augt 2016 to May 2017), and executive vice president, interim chief financial officer and member of the office of the president (May 2017 to March 2018) for Infystem Holdings, Inc., a supplier of infion services to oncologists in the United States. Mr. Downs spent 10 years in investment banking with vario firms including Citigroup. Mr. Downs served as a director of EBET, Inc., a technology company developing and operating platforms foced on esports and competitive gaming, from March 2021 to July 2024. Mr. Downs is a graduate of the United States Military Academy at st Point where he earned his Bachelor of Science. Mr. Downs earned his MBA at Columbia Biness School and his Master of Science in Accounting at the University of Hoton Clear Lake. Mr. Downs is a Certified Public Accountant in Utah and Texas.
- Rami Levin
拉米·莱文自2024年11月起担任生命科学搜索公司GENerX Life的董事会顾问，并自2024年1月起担任私人控股的咨询和领导力发展公司The Outcomes Group的创始人兼首席执行官。此前，Levin先生于2022年5月至2024年1月期间担任临床阶段生物制药公司ImStem Biotechnology的首席执行官。2019年10月至2022年5月，他担任临床阶段生物制药公司Saniona的总裁兼首席执行官。Levin先生还曾于2017年4月至2021年6月在非营利组织Life Science Cares的顾问委员会任职。Levin先生拥有特拉维夫大学生物学学士学位和MBA学位。
Rami Levin,has served as a Board Advisor for GENerX Life, a life sciences search firm, since November 2024, and as Founder and Chief Executive Officer of The Outcomes Group, a privately held advisory and leadership-development firm, since January 2024. Previously, Mr. Levin served as Chief Executive Officer of ImStem Biotechnology, a clinical-stage biopharmaceutical company, from May 2022 to January 2024. From October 2019 to May 2022, he was President and Chief Executive Officer of Saniona, a clinical-stage biopharmaceutical company. Mr. Levin also served on the Board of Advisors for Life Science Cares, a nonprofit organization, from April 2017 to June 2021. Mr. Levin holds a B.Sc. in Biology and an MBA from Tel Aviv University.- 拉米·莱文自2024年11月起担任生命科学搜索公司GENerX Life的董事会顾问，并自2024年1月起担任私人控股的咨询和领导力发展公司The Outcomes Group的创始人兼首席执行官。此前，Levin先生于2022年5月至2024年1月期间担任临床阶段生物制药公司ImStem Biotechnology的首席执行官。2019年10月至2022年5月，他担任临床阶段生物制药公司Saniona的总裁兼首席执行官。Levin先生还曾于2017年4月至2021年6月在非营利组织Life Science Cares的顾问委员会任职。Levin先生拥有特拉维夫大学生物学学士学位和MBA学位。
- Rami Levin,has served as a Board Advisor for GENerX Life, a life sciences search firm, since November 2024, and as Founder and Chief Executive Officer of The Outcomes Group, a privately held advisory and leadership-development firm, since January 2024. Previously, Mr. Levin served as Chief Executive Officer of ImStem Biotechnology, a clinical-stage biopharmaceutical company, from May 2022 to January 2024. From October 2019 to May 2022, he was President and Chief Executive Officer of Saniona, a clinical-stage biopharmaceutical company. Mr. Levin also served on the Board of Advisors for Life Science Cares, a nonprofit organization, from April 2017 to June 2021. Mr. Levin holds a B.Sc. in Biology and an MBA from Tel Aviv University.